HomeCategory

Blog

How common is Bone Cancer?

Bone cancer, while rare, can be quite serious. Acupath Laboratories, Inc. would like to share some key points based on information available: Statistics and Types of Bone Cancer: • Incidence: Primary bone cancers are very uncommon, comprising less than 1% of all cancers. • Gender Differences: In 2024, an estimated 3,970 new cases of primary...

Differences Between Urinalysis Urine Cytology AcuURO17

What are the differences between urinalysis, urine cytology, and the AcuURO-17? While urine cytology, urinalysis, and AcuURO-17 are all diagnostic tests that involve urine, they are quite different. Urinalysis and urine cytology indeed play crucial roles and are essential diagnostic tools in the field of urology and contribute significantly to the early detection and management...

What is Flow Cytometry?

Understanding the Importance of Flow Cytometry: Flow cytometry is a high sensitivity laboratory technique that plays a crucial role in diagnosing and staging leukemias and lymphomas, and for monitoring the treatment progress of cancer patients. Flow is also critical for monitoring infectious diseases (like HIV) and auto-immune disorders (like Lupus). Flow Cytometry Test Overview: Cells...

National Summer Sun Safety Month – August

UV RAYS FROM THE SUN CAUSES DNA DAMAGE, WHICH LEADS TO SKIN CANCER, EYE ISSUES AND PREMATURE AGING. The five-year survival rates for patients diagnosed with melanoma are: 99 percent when the cancer is localized 74 percent when the cancer has spread nearby 36 percent when the cancer has metastasizedNearly 20 Americans die from melanoma...

Bladder Cancer: How It Affects Men vs. Women

The common thought surrounding bladder cancer is that it is a disease that older men are diagnosed with. Fact is that men are more likely to be diagnosed earlier than women. When men present with blood in their urine (hematuria), it will be addressed and diagnosed quickly. Many women ignore hematuria in their urine because...

COLORECTAL CANCER – WHO IS AT RISK?

At the start of the COVID-19 pandemic, colorectal cancer screenings dropped roughly 90% and diagnoses fell by 32%. Regular colorectal cancer screening is one of the most powerful tools against colorectal cancer. Screening can often find colorectal cancer early, when it’s small, hasn’t spread, and might be easier to treat. At Acupath, Molecular Biomarker testing helps...